anzupgo - delgocitinib cream
(Delgocitinib)Leo Pharma, Inc
Janus Kinase Inhibitors [MoA] class drugs
8 results
baricitinib - baricitinib tablet, film coated
(Baricitinib)Eli Lilly And Companycibinqo - abrocitinib tablet, film coated
(Abrocitinib)Pfizer Laboratories Div Pfizer Inccibinqo - abrocitinib tablet, film coated
(Abrocitinib)U.S. PharmaceuticalsUsage: CIBINQO treats moderate-to-severe atopic dermatitis in adults and pediatric patients 12 and older whose disease is not adequately controlled by other systemic therapies, including biologics, or when those therapies are inadvisable. Not recommended with other JAK inhibitors, biologic immunomodulators, or immunosuppressants.jakafi - ruxolitinib tablet
(Ruxolitinib)Incyte CorporationUsage: Jakafi treats intermediate or high-risk myelofibrosis and polycythemia vera (in adults intolerant of or unresponsive to hydroxyurea). Also indicated for steroid-refractory acute and chronic graft-versus-host disease in adults and pediatric patients 12 and older.olumiant - baricitinib tablet, film coated
(Baricitinib)Eli Lilly And CompanyUsage: Olumiant (baricitinib) treats adults with moderately-to-severely active rheumatoid arthritis after TNF blocker failure, hospitalized adults with COVID-19 requiring oxygen or mechanical ventilation, and adults with severe alopecia areata.rinvoq - upadacitinib tablet, extended release
(Upadacitinib)Abbvie Inc.Usage: RINVOQ is a JAK inhibitor indicated for adults and some pediatric patients with rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis, generally after inadequate response to TNF blockers.vonjo - pacritinib capsule
(Pacritinib)Sobi, Inc.Usage: Vonjo treats adults with intermediate or high-risk primary or secondary myelofibrosis (post-polycythemia vera or post-essential thrombocythemia) with a platelet count below 50 × 10⁹/L. Approved under accelerated approval based on spleen volume reduction.